Immunogenicity and Safety of Two Tetravalent (Measles, Mumps, Rubella, Varicella) Vaccines Coadministered With Hepatitis A and Pneumococcal Conjugate Vaccines to Children Twelve to Fourteen Months of Age
Authors:
- Nicola P. KleinNKNicola P. Klein
- Julie S. ShepardJSJulie S. Shepard
- Michael LeonardiMLMichael Leonardi
- Steven ShapiroSSSteven Shapiro
- Martin SchearMSMartin Schear
- Maurice A. MufsonMMMaurice A. Mufson
- Judith M. MartinJMJudith M. Martin
- Meera VarmanMVMeera Varman
- Stanley GroggSGStanley Grogg
- Arnold LondonALArnold London
- Pierre CambronPCPierre Cambron
- 1 August 2012
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 31 (8) , e133-e140
Abstract
This study compared single-dose tetravalent measles, mumps, rubella, varicella vaccine, Priorix-Tetra, stored refrigerated (GSK+4C) or frozen (GSK-20C), with ProQuad (Merck-20C), when coadministered with hepatitis A vaccine (HAV) and 7-valent pneumococcal conjugate vaccine (PCV7). Multicenter, observer-blind phase 2 study in 1783 healthy 12-14 month olds randomized to: GSK+4C (n = 705), GSK-20C (n = 689) or Merck-20C (n = 389), administered concomitantly with HAV (Havrix) and PCV7 (Prevnar). Seroresponse rates and antibody geometric mean concentrations/titers were determined from enzyme-linked immunosorbent assay and neutralization assays. Reactogenicity and safety were assessed. Seroresponse rates (day 42) were >97% for measles and rubella viruses and >92% for mumps virus, in all groups. Noninferiority of both GSK+4C and GSK-20C vaccines versus Merck-20C was demonstrated for seroresponse rates to measles, mumps and rubella viruses (lower 97.5% confidence interval above -5%, -10% and -5%, respectively). For varicella-zoster virus, seroresponse rates were 57.1%, 69.8% and 86.7% in the GSK+4C, GSK-20C and Merck-20C groups, respectively. Noninferiority was not shown for either GSK vaccine (lower 97.5% confidence intervals <-15%). Geometric mean concentration ratios for anti-varicella-zoster virus demonstrated noninferiority (lower 97.5% confidence interval ≥ 0.5) versus Merck-20C for GSK-20C only. Geometric mean concentration ratios for antibodies to HAV and to PCV7 pneumococcal serotypes also met criteria for noninferiority for both GSK groups compared with Merck-20C. GSK vaccine safety was observed comparable to Merck-20C. Localized but not generalized measles/rubella-like rash and grade 3 fever was reported slightly more frequently with GSK vaccines, but antipyretic use was similar. The incidence of subjects experiencing at least 1 serious adverse event was 2.0%, 2.9% and 1.8% in the GSK+4C, GSK-20C and Merck-20C groups, respectively. Noninferiority of both GSK measles, mumps, rubella, varicella vaccines versus Merck-20C was demonstrated for responses to measles, mumps and rubella viruses but was not fully demonstrated for varicella-zoster virus. The vaccines showed acceptable reactogenicity/safety when coadministered with HAV and PCV7.Keywords
This publication has 22 references indexed in Scilit:
- Evaluation of Pneumococcal Polysaccharide Immunoassays Using a 22F Adsorption Step with Serum Samples from Infants Vaccinated with Conjugate VaccinesClinical and Vaccine Immunology, 2010
- Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care settingVaccine, 2009
- Varicella Prevention in the United States: A Review of Successes and ChallengesPediatrics, 2008
- Immunogenicity and Safety Assessments After One and Two Doses of a Refrigerator-Stable Tetravalent Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children During the Second Year of LifeThe Pediatric Infectious Disease Journal, 2008
- Changing Varicella Epidemiology in Active Surveillance Sites—United States, 1995–2005The Journal of Infectious Diseases, 2008
- Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12–23 monthsEuropean Journal of Pediatrics, 2007
- An Economic Analysis of the Current Universal 2-dose measles-mumps-rubella Vaccination Program in the United StatesThe Journal of Infectious Diseases, 2004
- Measles Elimination in the United StatesThe Journal of Infectious Diseases, 2004
- A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX? in healthy children*1Vaccine, 2002
- Sensitive neutralization test for virus antibodyArchives of Virology, 1978